The Role of Systemic Therapy in Melanoma Brain Metastases

A Narrative Review

Kainat Saleem; Diwakar Davar


Chin Clin Oncol. 2022;11(3):24 

In This Article


Without imposing any restriction on the publication language and publication time, the PubMed, Scopus and Embase databases were systematically queried to obtain records published before April 1, 2022, with the following keywords: ("melanoma" OR "brain" OR "melanoma brain metastases") and ("epidemiology") and ("tumor microenvironment" OR "TME" or "pathway") and ("targeted therapy" OR "BRAF" OR "MEK") and ("immune therapy" OR "programmed cell death 1" OR "PD-1" OR "PD1" OR "programmed death 1 receptor" OR "cytotoxic T-lymphocyte-associated antigen 4" OR "CD152" OR "CTLA-4") (Table 1). We also used the Emtree terms to increase the sensitivity of our systematic search.

Studies with the following eligibility criteria were included in our study: (I) investigations that studied the effects of targeted or immune therapies on MBM, and (II) studies that described the epidemiology and/or translational molecular immunobiology of MBM. Based on the following criteria, studies were excluded from the current systematic review: (I) studies that did not meet the abovementioned inclusion criteria, (II) review papers, (III) meeting abstracts, (IV) perspectives, (V) book chapters, (VI) editorial articles, (VII) commentaries, (VIII) opinion articles, and (IX) duplicated papers.

Following the systematic search, the records were retrieved and reviewed. Initially, the titles and abstracts of all obtained papers were screened, and those that did not meet criteria were excluded. Subsequently, the full text of all remaining papers and supplementary data were reviewed for consideration to be included in the current study.

The following data were extracted from the included studies: (I) the first author, (II) the year of publication, and (III) the main findings.